All News

Found 201 articles

• Alnylam Announces Promotion of Dr. Akshay Vaishnaw to President

  1/4/2022

  Alnylam Pharmaceuticals, Inc. today announced that Akshay Vaishnaw, M.D., Ph.D. has been appointed President.

• Scholar Rock to Present at the 40th Annual J.P. Morgan Healthcare Conference

  1/4/2022

  Scholar Rock today announced that management will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 7:30 a.m. ET.

• Scholar Rock Announces Design of Phase 3 SAPPHIRE Clinical Trial Evaluating Apitegromab in Non-Ambulatory Patients with Type 2 and Type 3 Spinal Muscular Atrophy (SMA)

  11/30/2021

  Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the study design for SAPPHIRE, a Phase 3 trial of apitegromab, a selective inhibitor of the activation of latent myostatin.

• Scholar Rock Presents Data from Part A of the DRAGON Phase 1 Trial Evaluating SRK-181 as Monotherapy and in Combination with Anti-PD-(L)1 for the Treatment of Solid Tumors -- Announces Advancement into Part B

  11/12/2021

  Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today presented initial clinical data from Part A of its DRAGON Phase 1 proof-of-concept trial (NCT04291079) at the ongoing 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting.

• Scholar Rock Reports Third Quarter 2021 Financial Results and Highlights Business Progress

  11/9/2021

  Scholar Rock Reports Third Quarter 2021 Financial Results and Highlights Business Progress

• Scholar Rock to Present at Upcoming Healthcare Conferences - Nov 02, 2021

  11/2/2021

  Scholar Rock, a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, announced that management will participate in the following upcoming investor conferences.

• Scholar Rock to Present Apitegromab TOPAZ Phase 2 Pharmacologic Data at the 2021 World Congress of Neurology

  10/3/2021

  Scholar Rock, a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, announced an e-poster presentation of clinical results from the TOPAZ Phase 2 trial that evaluated apitegromab in patients with Type 2 and Type 3 spinal muscular atrophy at the 25th World Congress of Neurology taking place October 3-7, 2021.

• Scholar Rock Presents Exploratory Responder Analysis on Efficacy Data from the Apitegromab TOPAZ Phase 2 Trial at the Child Neurology Society Annual Meeting

  9/30/2021

  Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced a late breaker poster presentation as part of the 50th Child Neurology Society (CNS) Annual Meeting taking place September 29-October 2, 2021 Virtual and Live in Boston, MA.

•  Scholar Rock Announces Issuance of U.S. Patent Protecting SRK-181, an Inhibitor of TGFβ1 Activation

  9/28/2021

  Scholar Rock Announces Issuance of U.S. Patent Protecting SRK-181, an Inhibitor of TGFβ1 Activation

•  Scholar Rock Presents Additional Data Analyses from the Apitegromab TOPAZ Phase 2 Trial at the World Muscle Society 2021 Virtual Congress

  9/23/2021

    Scholar Rock Presents Additional Data Analyses from the Apitegromab TOPAZ Phase 2 Trial at the World Muscle Society 2021 Virtual Congress

• Scholar Rock to Present at the 2021 Cantor Virtual Global Healthcare Conference

  9/22/2021

  Scholar Rock today announced that management will present at the 2021 Cantor Virtual Global Healthcare Conference on Wednesday, September 29 th , 2021 at 11:20 a.m. ET.

• 

  BioSpace Movers & Shakers, Aug. 20

  8/20/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Scholar Rock Appoints Caryn Parlavecchio as Chief Human Resources Officer

  8/16/2021

  Scholar Rock, a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, announced the appointment of Caryn Parlavecchio as Chief Human Resources Officer.

• Scholar Rock Reports Second Quarter 2021 Financial Results and Highlights Business Progress

  8/10/2021

  Scholar Rock, a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, reported financial results for the second quarter ended June 30, 2021, and highlighted recent progress and upcoming milestones for its pipeline programs.

• Scholar Rock to Present at the 2021 Wedbush PacGrow Healthcare Conference

  8/5/2021

  Scholar Rock, a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, announced that management will present at the 2021 Wedbush PacGrow Healthcare Conference on Wednesday, August 11th, 2021 at 9:10 a.m. ET.

• Scholar Rock Announces Leadership Change

  8/3/2021

  Nagesh Mahanthappa, Ph.D., MBA, Scholar Rock’s founding chief executive, returns as Interim Chief Executive Officer as CEO Tony Kingsley departs

• 

  BioSpace Movers & Shakers, July 30, 2021

  7/30/2021

  Biopharma and life science companies strengthen their leadership teams and boards with these Movers & Shakers.

• Abata Therapeutics Strengthens Board of Directors

  7/28/2021

  Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with severe autoimmune and inflammatory diseases, today announced that it has strengthened its board of directors with the addition of Nagesh Mahanthappa Ph.D., M.B.A., and Valerie Odegard, Ph.D.

• Scholar Rock to Present Apitegromab TOPAZ Phase 2 Trial Results Highlighting Pharmacokinetic (PK) and Pharmacodynamic (PD) Data at the 2021 European Academy of Neurology Congress

  6/18/2021

  Scholar Rock today announced an oral e-presentation of clinical results from the TOPAZ Phase 2 trial.

• Scholar Rock Presents TOPAZ Phase 2 Data Showing the Transformative Potential of Apitegromab in Patients with Type 2 and 3 Spinal Muscular Atrophy (SMA) at the 2021 Virtual SMA Research & Clinical Care Meeting

  6/11/2021

  Scholar Rock today announced an oral presentation of TOPAZ Phase 2 trial results by the lead principal investigator, Thomas Crawford, M.D. of Johns Hopkins Medicine, at the Cure SMA Annual SMA Conference.